G1 Therapeutics Faces Setback in Phase 3 Trial
Shares of G1 Therapeutics took a major hit, falling 46% to $2.44 in after-hours trading on Monday, following an update on its Phase 3 trilaciclib combination trial. Trial Continuation Recommended…
Shares of G1 Therapeutics took a major hit, falling 46% to $2.44 in after-hours trading on Monday, following an update on its Phase 3 trilaciclib combination trial. Trial Continuation Recommended…